Jalleh RJ, Umapathysivam MM, Plummer MP, Deane A, Jones KL, Horowitz M
Methods: Seven databases were searched until June 2021 for randomized controlled trials with a duration of at least 12 weeks, evaluating the effects of combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors
Wadhwa V, Mehta D, Jobanputra Y, Lopez R, Thota PN, Sanaka MR
Daylight Exposure, Mental Health Disorders (00:51:35) Major Depression & Light Exposure
Maszka P, Kwasniak-Butowska M, Cysewski D, Slawek J, Smolenski RT, Tomczyk M
However the usability study (PREFER), in which the injection devices of dulaglutide OW and semaglutide OW were compared, had a number of limitations, including the devices being used once only, injections being performed into an injection pad rather than participants, and the limited generalisability outside of the USA [80]